Livzon Pharmaceutical Group Inc. announced in the evening that, based on the principle of prudence, asset impairment tests were conducted on assets with indications of impairment within the scope of the consolidated financial statements of the company and its subsidiaries as of December 31, 2024, and corresponding provisions for impairment were made for those assets with indications of impairment. This provision for asset impairment will reduce the net income attributable to the parent company's shareholders by 0.106 billion yuan in 2024.